Caspase-3-generated cytokeratin-18 is the most studied biomarker for NASH diagnosis but has limited sensitivity for NASH stage screening (6); hence, other putative biomarkers (inflammatory markers, adipokines, and others) are emerging (7). Here, KRT18 is linked to metabolic dysfunction-associated steatohepatitis.